权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic regulation of pancreatic cancer

胰腺癌的表观遗传调控

基本信息

批准号：
8646377
负责人：
Matthias Hebrok
金额：
$ 32.73万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-03 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8646377
关键词：
Ablation Acinar Cell Address Adult Benign Cancer Etiology Cells Cessation of life Chromatin Remodeling Factor Clinical Code Collaborations Cues Data Development Diagnosis Duct (organ) structure Ductal Early Diagnosis Enzymes Epigenetic Process Epithelium Gene Expression Gene Targeting Genes Goals Growth Human Intraepithelial Neoplasia Knowledge Lesion Longevity Malignant Neoplasms Malignant neoplasm of pancreas Mediating Medicine Metaplasia Molecular Molecular Analysis Morphology Mucinous Mus Neoplasms Neoplastic Cell Transformation Oncogenic Pancreas Pancreatic Adenocarcinoma Pancreatic Intraepithelial Neoplasia Pancreatic duct Papillary Physiological Population Process Proteins Regulation Role Sampling Series Specimen Staging Stem cells Testing Therapeutic Intervention Transgenic Animals Transgenic Mice Transgenic Model United States Universities Utah base cell type chromatin remodeling combat human disease insight intraepithelial mouse model mutant neoplastic new therapeutic target novel novel diagnostics novel marker outcome forecast overexpression prevent progenitor public health relevance response tool tumor tumor initiation

项目摘要

Project Summary/Abstract Pancreatic adenocarcinoma (PDA) carries one of the most dismal prognoses in all of medicine and is currently the 4th leading cause of cancer death in the United States. Several subtypes of PDA have been identified that vary greatly with regard to their lethality. Preliminary studies presented in this proposal support the notion that diverse PDA subtypes form from distinct pancreas cell populations, including duct and acinar cells. Importantly, we have identified a specific gene coding for a chromatin remodeling enzyme that modulates the response to tumor-inducing cues in these different cell types. Elimination of the gene in duct cells of transgenic mice supports the development of morphological and molecular changes associated with the formation of the more benign PDA subtype. In contrast, the gene product is required for the development of the more aggressive form of PDA in acinar cells. Thus, we have identified a novel regulator of PDA subtype formation. We propose to test how the loss of the chromatin remodeler changes the differentiation state of pancreatic duct cells and makes them prone to develop the more benign subset of pancreatic cancer. Conversely, we present an experimental strategy to test how the loss of this gene prevents formation of the more aggressive form of PDA from acinar cells. We have already identified potential target genes for both the aggressive and more benign subtypes and will test whether manipulation of these factors initiates or prevents the early stages of benign and aggressive tumor formation. Finally, we are focusing on one particular target that we recently characterized to be essential for the development of the aggressive form. In this application we will test whether changes in gene expression of that factor can interfere with the development of the PDA subtypes. Throughout the proposal, we are using state of the art transgenic animals and molecular tools to address the questions outlined above. Furthermore, we have established close collaborations with clinical colleagues both at UCSF and at the University of Utah who will provide us with specimen of human cancer samples to test and verify that new factors identified in our mouse models have relevance to the human disease. It is our goal to identify both novel diagnostic markers that can be used for the early detection of the subsets of PDA as well as novel therapeutic targets that could be exploited to attack the cancer ones it has formed. These studies fulfill a critical gap as our knowledge about the formation and molecular mechanisms underlying the development of the more benign form of pancreatic cancer is limited. By understanding how the more benign cancer forms and how this differs from the formation of the aggressive form, we hope to gain critical insights into how one can manipulate the aggressive tumors to reduce it growth potential.

项目总结/文摘